Want to see TSE:MDP full AI Analyst Report?
Top Page
Medexus Pharmaceuticals Inc
(TSX:MDP)
Select Model
Select Model
Rating:63Neutral
Price Target:
C$5.50
▲(8.70% Upside)
Action:Reiterated
Date:08/17/26
The score is supported by improving financial stability (materially lower leverage), solid gross profitability and operating profitability, and strong technical momentum with price above key moving averages. Offsetting this are still-weak quality signals in cash generation (TTM free cash flow slightly negative) and valuation constraints from a negative P/E. The latest earnings call adds a positive tilt due to strong GRAFAPEX adoption and reiterated revenue targets, despite near-term working-capital and net-debt headwinds.
Positive Factors
GRAFAPEX Adoption
Broad institutional uptake and repeat ordering indicate durable product acceptance rather than one-time stocking. Continued patient-demand growth can support recurring revenue and strengthen Medexus’s position in specialty hospital care.
Negative Factors
Persistent Net Losses
Despite positive gross and operating margins, recurring net losses indicate that the business has not yet converted commercialization activity into durable bottom-line profitability. Negative ROE also shows the equity base remains underproductive.
Read all positive and negative factors
Positive Factors
Negative Factors
GRAFAPEX Adoption
Broad institutional uptake and repeat ordering indicate durable product acceptance rather than one-time stocking. Continued patient-demand growth can support recurring revenue and strengthen Medexus’s position in specialty hospital care.
Read all positive factors
Medexus Pharmaceuticals Inc (MDP) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$159.02M
Dividend YieldN/A
Average Volume (3M)49.56K
Price to Earnings (P/E)―
Beta (1Y)0.98
Revenue Growth-3.16%
EPS Growth-345.50%
CountryCA
Employees90
SectorHealthcare
Sector Strength45
IndustryMedical - Pharmaceuticals
Share Statistics
EPS (TTM)-0.07
Shares Outstanding31,425,983
10 Day Avg. Volume43,735
30 Day Avg. Volume49,564
Financial Highlights & Ratios
PEG Ratio0.25
Price to Book (P/B)2.06
Price to Sales (P/S)1.02
P/FCF Ratio27.10
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$6.50Price Target Upside28.46% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.18
Revenue Forecast (FY)C$117.21M
Medexus Pharmaceuticals Inc Business Overview & Revenue Model
Company Description
Medexus Pharmaceuticals Inc. operates as a pharmaceutical company in Canada and the United States. The company focuses on various therapeutic areas comprising allergy, dermatology, hematology, oncology, rheumatology, and rare diseases. Its primary...
How the Company Makes Money
Medexus primarily makes money by generating revenue from the sale of its specialty pharmaceutical products in the markets where it holds commercialization rights. Its core revenue stream is product sales to customers (e.g., wholesalers, hospitals,...
Medexus Pharmaceuticals Inc Earnings Call Summary
Earnings Call Date:Aug 10, 2026
(Q1-2027)
| % Change Since: |
Next Earnings Date:Nov 11, 2026
Earnings Call Sentiment Positive
The call highlights substantial commercial momentum for GRAFAPEX (strong quarter, double-digit demand growth vs prior year, repeat ordering, and reiterated near- and long-term revenue targets) and measurable improvements in revenue, adjusted EBITDA and gross profit. Offsetting items include a negative swing in operating cash flow driven by working capital timing, a $5.2M increase in net debt, modest margin compression caused by prior-year comparatives, higher SG&A, and product-level risks (Rasuvo ANDA/tariff uncertainty and concentration of growth in GRAFAPEX). On balance, the positives around product adoption, revenue growth and EBITDA expansion materially outweigh the manageable near-term cash and leverage headwinds.Positive Updates
GRAFAPEX Strong Commercial Launch
Product-level net revenue of $4.9M in fiscal Q1 2027; product-level performance net of working capital was accretive to quarterly operating cash flows. Wholesaler data (as of June 30, 2026) shows 75 healthcare institutions have ordered GRAFAPEX and 54 have placed repeat orders, indicating adoption and repeat usage.
Negative Updates
Operating Cash Flow Swing and Working Capital Timing
Cash used by operating activities was $0.7M in Q1 2027 versus $3.9M cash provided in the prior-year period — a negative swing of $4.6M primarily driven by settlement of year-end payables and working capital timing differences.
Read all updates
Q1-2027 Updates
Positive
Negative
GRAFAPEX Strong Commercial Launch
Product-level net revenue of $4.9M in fiscal Q1 2027; product-level performance net of working capital was accretive to quarterly operating cash flows. Wholesaler data (as of June 30, 2026) shows 75 healthcare institutions have ordered GRAFAPEX and 54 have placed repeat orders, indicating adoption and repeat usage.
Read all positive updates
Company Guidance
Medexus reiterated that GRAFAPEX is expected to deliver product-level net revenue of $30–$32 million in fiscal 2027 and to reach approximately $100–$175 million in annual product-level net revenue within five years (implying ~29%–42% market share); in Q1 FY27 GRAFAPEX generated $4.9M of product-level net revenue (underlying patient demand $4.8M, +23% vs Q4 FY26 and +118% vs Q1 FY26), with 75 institutions having ordered and 54 repeat customers, and ~$3.2M of GRAFAPEX personnel/infrastructure investment in the quarter (product-level performance net of working capital was accretive to cash flow). Company-wide Q1 metrics: total net revenue $28.6M (vs $24.6M), gross profit $15.9M, gross margin 55.6% (adjusted gross margin 63.8%), adjusted EBITDA $4.7M (vs $3.4M), operating income $2.1M (vs $0.9M), net income $0.5M, cash used by operations $0.7M, net debt $20.9M (vs $15.7M at Mar 31) and net debt/adjusted EBITDA 1.18x; inventory was ~1 month and Medicare NTAP was confirmed for another year. Management also noted potential tariff exposure (~15% worst-case) on some products and expects to generate meaningful operating cash flow in FY27.Medexus Pharmaceuticals Inc Financial Statement Overview
Summary
Income Statement
52
Neutral
Balance Sheet
66
Positive
Cash Flow
48
Neutral
| Breakdown | TTM | Mar 2026 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 102.56M | 99.33M | 113.05M | 108.10M | 76.70M | 79.66M |
| Gross Profit | 56.06M | 54.41M | 59.51M | 60.04M | 37.93M | 42.01M |
| EBITDA | 12.56M | 12.66M | 19.28M | 14.65M | 14.55M | -23.61M |
| Net Income | -2.38M | -2.39M | -214.00K | 1.22M | -2.88M | -28.26M |
Balance Sheet | ||||||
| Total Assets | 141.86M | 147.28M | 155.73M | 161.33M | 139.22M | 148.51M |
| Cash, Cash Equivalents and Short-Term Investments | 5.34M | 6.52M | 5.25M | 13.07M | 10.02M | 18.70M |
| Total Debt | 26.21M | 22.26M | 49.90M | 70.08M | 54.86M | 44.87M |
| Total Liabilities | 93.88M | 98.29M | 125.41M | 138.88M | 121.43M | 130.50M |
| Stockholders Equity | 47.99M | 48.99M | 30.32M | 22.45M | 17.79M | 18.02M |
Cash Flow | ||||||
| Free Cash Flow | -1.21M | 3.72M | 18.45M | -1.81M | -8.89M | -5.72M |
| Operating Cash Flow | 13.84M | 18.87M | 18.71M | -1.44M | -1.18M | 5.04M |
| Investing Cash Flow | -17.46M | -17.40M | -3.48M | -1.72M | -8.20M | -11.70M |
| Financing Cash Flow | -249.08K | -18.92M | -23.05M | 6.41M | 663.00K | 18.68M |
Medexus Pharmaceuticals Inc Technical Analysis
Neutral
5.06
Price Trends
5.05
Positive
4.52
Positive
3.74
Positive
Market Momentum
0.04
Positive
47.91
Neutral
40.09
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:MDP, the sentiment is Neutral. The current price of 5.06 is below the 20-day moving average (MA) of 5.18, above the 50-day MA of 5.05, and above the 200-day MA of 3.74, indicating a neutral trend. The MACD of 0.04 indicates Positive momentum. The RSI at 47.91 is Neutral, neither overbought nor oversold. The STOCH value of 40.09 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TSE:MDP.
Medexus Pharmaceuticals Inc Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
86 Outperform | C$180.60M | 18.15 | 22.92% | 1.35% | 40.91% | 19.88% | |
63 Neutral | C$159.02M | -47.64 | -4.72% | ― | -3.16% | -345.50% | |
58 Neutral | C$64.40M | -2.56 | -25.01% | ― | 13.60% | 11.06% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | C$26.09M | -3.53 | -54.73% | ― | 38.25% | -450.85% | |
46 Neutral | C$45.50M | -4.74 | 117.02% | ― | -62.34% | 9.80% | |
41 Neutral | C$38.48M | -7.83 | -403.29% | ― | ― | -49.66% |
* Healthcare Sector Average
TSE:MDP
Medexus Pharmaceuticals Inc
5.06
1.94
62.18%
TSE:MPH
Medicure
2.50
1.30
108.33%
TSE:RX
Biosyent
15.97
4.15
35.12%
TSE:VEXT
Vext Science
0.26
-0.06
-18.75%
TSE:VM
Voyageur Pharmaceuticals
0.17
<0.01
4.29%
TSE:BNXT
BioNxt Solutions
0.35
-0.57
-61.96%
Medexus Pharmaceuticals Inc Corporate Events
Business Operations and StrategyFinancial Disclosures
Medexus Q1 Profitability Surges on Record GRAFAPEX Performance
Positive
Aug 10, 2026
Medexus reported a strong fiscal Q1 2027, driven by the best quarter to date for GRAFAPEX, which generated $4.9 million in product-level net revenue against $3.2 million in related personnel and infrastructure costs. Management expects GRAFAPEX to...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.